vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Clearwater Analytics Holdings, Inc. (CWAN). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $217.5M, roughly 1.3× Clearwater Analytics Holdings, Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -5.4%, a 101.7% gap on every dollar of revenue. On growth, Clearwater Analytics Holdings, Inc. posted the faster year-over-year revenue change (72.0% vs 9.4%). Over the past eight quarters, Clearwater Analytics Holdings, Inc.'s revenue compounded faster (45.5% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Clearwater Analytics Holdings, Inc. is an American software-as-a-service (SaaS) fintech company that provides automated investment accounting, performance, compliance, and risk reporting worldwide. Clearwater is a publicly traded company headquartered in Boise, Idaho, with additional offices in London, Edinburgh, New York City and Noida.
ACAD vs CWAN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $217.5M |
| Net Profit | $273.6M | $-11.8M |
| Gross Margin | 90.8% | 67.2% |
| Operating Margin | 6.1% | -3.1% |
| Net Margin | 96.3% | -5.4% |
| Revenue YoY | 9.4% | 72.0% |
| Net Profit YoY | 90.3% | -102.8% |
| EPS (diluted) | $1.61 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $217.5M | ||
| Q3 25 | $278.6M | $205.1M | ||
| Q2 25 | $264.6M | $181.9M | ||
| Q1 25 | $244.3M | $126.9M | ||
| Q4 24 | $259.6M | $126.5M | ||
| Q3 24 | $250.4M | $115.8M | ||
| Q2 24 | $242.0M | $106.8M | ||
| Q1 24 | $205.8M | $102.7M |
| Q4 25 | $273.6M | $-11.8M | ||
| Q3 25 | $71.8M | $-10.3M | ||
| Q2 25 | $26.7M | $-23.2M | ||
| Q1 25 | $19.0M | $6.5M | ||
| Q4 24 | $143.7M | $419.3M | ||
| Q3 24 | $32.8M | $3.6M | ||
| Q2 24 | $33.4M | $-430.0K | ||
| Q1 24 | $16.6M | $1.9M |
| Q4 25 | 90.8% | 67.2% | ||
| Q3 25 | 92.2% | 65.6% | ||
| Q2 25 | 92.2% | 65.1% | ||
| Q1 25 | 91.7% | 73.3% | ||
| Q4 24 | 91.6% | 73.5% | ||
| Q3 24 | 92.5% | 72.9% | ||
| Q2 24 | 92.5% | 72.0% | ||
| Q1 24 | 88.8% | 72.6% |
| Q4 25 | 6.1% | -3.1% | ||
| Q3 25 | 12.8% | 3.2% | ||
| Q2 25 | 12.2% | -8.0% | ||
| Q1 25 | 7.9% | 5.6% | ||
| Q4 24 | 59.1% | 1.0% | ||
| Q3 24 | 12.6% | 6.3% | ||
| Q2 24 | 12.6% | 3.6% | ||
| Q1 24 | 7.4% | -0.2% |
| Q4 25 | 96.3% | -5.4% | ||
| Q3 25 | 25.8% | -5.0% | ||
| Q2 25 | 10.1% | -12.8% | ||
| Q1 25 | 7.8% | 5.1% | ||
| Q4 24 | 55.4% | 331.5% | ||
| Q3 24 | 13.1% | 3.1% | ||
| Q2 24 | 13.8% | -0.4% | ||
| Q1 24 | 8.0% | 1.8% |
| Q4 25 | $1.61 | $-0.04 | ||
| Q3 25 | $0.42 | $-0.04 | ||
| Q2 25 | $0.16 | $-0.09 | ||
| Q1 25 | $0.11 | $0.03 | ||
| Q4 24 | $0.86 | $1.65 | ||
| Q3 24 | $0.20 | $0.02 | ||
| Q2 24 | $0.20 | $0.00 | ||
| Q1 24 | $0.10 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $91.2M |
| Total DebtLower is stronger | — | $822.6M |
| Stockholders' EquityBook value | $1.2B | $2.0B |
| Total Assets | $1.6B | $3.0B |
| Debt / EquityLower = less leverage | — | 0.41× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $91.2M | ||
| Q3 25 | $258.0M | $64.1M | ||
| Q2 25 | $253.6M | $71.9M | ||
| Q1 25 | $217.7M | $282.9M | ||
| Q4 24 | $319.6M | $255.5M | ||
| Q3 24 | $155.1M | $305.8M | ||
| Q2 24 | $177.1M | $257.9M | ||
| Q1 24 | $204.7M | $267.6M |
| Q4 25 | — | $822.6M | ||
| Q3 25 | — | $838.9M | ||
| Q2 25 | — | $878.1M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $43.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $2.0B | ||
| Q3 25 | $917.3M | $2.0B | ||
| Q2 25 | $822.4M | $2.0B | ||
| Q1 25 | $765.2M | $1.1B | ||
| Q4 24 | $732.8M | $1.0B | ||
| Q3 24 | $577.2M | $403.2M | ||
| Q2 24 | $516.7M | $380.6M | ||
| Q1 24 | $464.0M | $406.2M |
| Q4 25 | $1.6B | $3.0B | ||
| Q3 25 | $1.3B | $3.0B | ||
| Q2 25 | $1.2B | $3.0B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $976.9M | $623.5M | ||
| Q2 24 | $914.1M | $585.1M | ||
| Q1 24 | $855.1M | $547.8M |
| Q4 25 | — | 0.41× | ||
| Q3 25 | — | 0.42× | ||
| Q2 25 | — | 0.45× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $55.3M |
| Free Cash FlowOCF − Capex | — | $52.3M |
| FCF MarginFCF / Revenue | — | 24.0% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $164.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $55.3M | ||
| Q3 25 | $74.3M | $49.0M | ||
| Q2 25 | $64.0M | $47.1M | ||
| Q1 25 | $20.3M | $24.5M | ||
| Q4 24 | $40.4M | $-29.2M | ||
| Q3 24 | $63.2M | $49.6M | ||
| Q2 24 | $25.0M | $43.9M | ||
| Q1 24 | $29.1M | $10.0M |
| Q4 25 | — | $52.3M | ||
| Q3 25 | $73.9M | $44.9M | ||
| Q2 25 | — | $44.1M | ||
| Q1 25 | — | $23.0M | ||
| Q4 24 | — | $-30.0M | ||
| Q3 24 | $63.2M | $48.1M | ||
| Q2 24 | — | $42.4M | ||
| Q1 24 | — | $8.6M |
| Q4 25 | — | 24.0% | ||
| Q3 25 | 26.5% | 21.9% | ||
| Q2 25 | — | 24.2% | ||
| Q1 25 | — | 18.2% | ||
| Q4 24 | — | -23.7% | ||
| Q3 24 | 25.2% | 41.5% | ||
| Q2 24 | — | 39.7% | ||
| Q1 24 | — | 8.4% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | 0.1% | 2.0% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | 3.76× | ||
| Q4 24 | 0.28× | -0.07× | ||
| Q3 24 | 1.93× | 13.66× | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | 5.29× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
CWAN
Segment breakdown not available.
